25,109 Shares in Xenon Pharmaceuticals Inc. $XENE Bought by Corient Private Wealth LLC

Corient Private Wealth LLC acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 25,109 shares of the biopharmaceutical company’s stock, valued at approximately $1,125,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Danske Bank A S bought a new position in shares of Xenon Pharmaceuticals in the 3rd quarter worth about $32,000. Blue Trust Inc. raised its stake in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the period. Kestra Advisory Services LLC bought a new position in Xenon Pharmaceuticals in the fourth quarter worth about $33,000. Aster Capital Management DIFC Ltd acquired a new position in Xenon Pharmaceuticals in the third quarter valued at approximately $39,000. Finally, Osaic Holdings Inc. grew its holdings in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Insider Transactions at Xenon Pharmaceuticals

In related news, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the transaction, the director directly owned 24,896 shares of the company’s stock, valued at $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.07% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on XENE shares. HC Wainwright raised their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Royal Bank Of Canada raised their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Guggenheim reissued a “buy” rating and set a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Jefferies Financial Group set a $100.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $77.20.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE opened at $60.30 on Thursday. Xenon Pharmaceuticals Inc. has a 1 year low of $30.00 and a 1 year high of $63.95. The firm has a market cap of $5.83 billion, a P/E ratio of -12.83 and a beta of 0.61. The stock has a fifty day moving average price of $54.83 and a two-hundred day moving average price of $50.07.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the prior year, the company posted ($0.83) earnings per share. On average, research analysts predict that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.